Filed: 2/8/2023ACC: 0001910264-23-000001
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $273.94M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$273.94M
Total AUM (reported)
23.19M
Total Shares
Allocation by class
COMMON STOCK$170.39M62.2%
COM$103.55M37.8%
Portfolio Concentration
Top 3$263.02M96.0%
4–10$10.92M4.0%
Top 3 weight
96.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 23.19M
Sole
Full voting authority
23.19M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
ARCELLX INC.
SOLEShares5.50M
TypeSH
Market value$170.39M
62.20%
Sole
5.50M
Shared
0.00
None
0.00
DESIGN THERAPEUTICS INC
SOLEShares6.53M
TypeSH
Market value$66.96M
24.44%
Sole
6.53M
Shared
0.00
None
0.00
ARS PHARMACEUTICALS
SOLEShares3.01M
TypeSH
Market value$25.67M
9.37%
Sole
3.01M
Shared
0.00
None
0.00
NKARTA INC.
SOLEShares1.33M
TypeSH
Market value$7.99M
2.92%
Sole
1.33M
Shared
0.00
None
0.00
EFFECTOR THERAPEUTICS INC
SOLEShares6.82M
TypeSH
Market value$2.93M
1.07%
Sole
6.82M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ARCELLX INC.SOLE | COMMON STOCK | 5.50M | SH | $170.39M 62.20% | 5.50M | 0.00 | 0.00 |
DESIGN THERAPEUTICS INCSOLE | COM | 6.53M | SH | $66.96M 24.44% | 6.53M | 0.00 | 0.00 |
ARS PHARMACEUTICALSSOLE | COM | 3.01M | SH | $25.67M 9.37% | 3.01M | 0.00 | 0.00 |
NKARTA INC.SOLE | COM | 1.33M | SH | $7.99M 2.92% | 1.33M | 0.00 | 0.00 |
EFFECTOR THERAPEUTICS INCSOLE | COM | 6.82M | SH | $2.93M 1.07% | 6.82M | 0.00 | 0.00 |